【石药集团:SYH2083滴眼液获临床试验批准】石药集团在港公告,本集团开发的化药1类创新药SYH2083滴眼液已获中国国家药品监督管理局批准,可于中国开展临床试验。本次获批的临床试验适应症为干眼症,该产品未来亦具备拓展至过敏性结膜炎等其他炎症性眼表疾病的临床潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.